Smithfield Trust’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41K | Hold |
239
| – | – | ﹤0.01% | 623 |
|
|
2025
Q4 | $48K | Buy |
239
+4
| +2% | +$726 | ﹤0.01% | 587 |
|
|
2025
Q3 | $37K | Hold |
235
| – | – | ﹤0.01% | 619 |
|
|
2025
Q2 | $36K | Hold |
235
| – | – | ﹤0.01% | 605 |
|
|
2025
Q1 | $36K | Hold |
235
| – | – | ﹤0.01% | 602 |
|
|
2024
Q4 | $43K | Hold |
235
| – | – | ﹤0.01% | 592 |
|
|
2024
Q3 | $47K | Sell |
235
-95
| -29% | -$19.7K | ﹤0.01% | 567 |
|
|
2024
Q2 | $67K | Sell |
330
-13
| -4% | -$2.95K | ﹤0.01% | 497 |
|
|
2024
Q1 | $92K | Buy |
343
+13
| +4% | +$3.1K | ﹤0.01% | 464 |
|
|
2023
Q4 | $79K | Hold |
330
| – | – | ﹤0.01% | 477 |
|
|
2023
Q3 | $65K | Buy |
330
+95
| +40% | +$19.5K | ﹤0.01% | 484 |
|
|
2023
Q2 | $48K | Hold |
235
| – | – | ﹤0.01% | 557 |
|
|
2023
Q1 | $47K | Hold |
235
| – | – | ﹤0.01% | 531 |
|
|
2022
Q4 | $52K | Hold |
235
| – | – | ﹤0.01% | 508 |
|
|
2022
Q3 | $47K | Hold |
235
| – | – | ﹤0.01% | 520 |
|
|
2022
Q2 | $50K | Hold |
235
| – | – | ﹤0.01% | 531 |
|
|
2022
Q1 | $67K | Hold |
235
| – | – | ﹤0.01% | 512 |
|
|
2021
Q4 | $89K | Hold |
235
| – | – | 0.01% | 468 |
|
|
2021
Q3 | $97K | Hold |
235
| – | – | 0.01% | 445 |
|
|
2021
Q2 | $87K | Hold |
235
| – | – | 0.01% | 463 |
|
|
2021
Q1 | $68K | Hold |
235
| – | – | ﹤0.01% | 509 |
|
|
2020
Q4 | $58K | Hold |
235
| – | – | ﹤0.01% | 500 |
|
|
2020
Q3 | $53K | Buy |
235
+120
| +104% | +$24.9K | ﹤0.01% | 487 |
|
|
2020
Q2 | $20K | Hold |
115
| – | – | ﹤0.01% | 622 |
|
|
2020
Q1 | $15K | Buy |
115
+45
| +64% | +$6.75K | ﹤0.01% | 615 |
|
|
2019
Q4 | $11K | Hold |
70
| – | – | ﹤0.01% | 689 |
|
|
2019
Q3 | $9K | Hold |
70
| – | – | ﹤0.01% | 748 |
|
|
2019
Q2 | $10K | Hold |
70
| – | – | ﹤0.01% | 722 |
|
|
2019
Q1 | $10K | Hold |
70
| – | – | ﹤0.01% | 674 |
|
|
2018
Q4 | $8K | Hold |
70
| – | – | ﹤0.01% | 683 |
|
|
2018
Q3 | $9K | Hold |
70
| – | – | ﹤0.01% | 737 |
|
|
2018
Q2 | $8K | Hold |
70
| – | – | ﹤0.01% | 758 |
|
|
2018
Q1 | $7K | Hold |
70
| – | – | ﹤0.01% | 766 |
|
|
2017
Q4 | $8K | Buy |
+70
| New | +$7.62K | ﹤0.01% | 784 |
|
Other funds holding CRL
VCM
VPM
Smithfield Trust's CRL Position: Q1 2026 in Review
Smithfield Trust held its Charles River Laboratories (CRL) position steady in Q1 2026 at 239 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #623.
Smithfield Trust first reported a position in CRL in Q4 2017 and has held it in 34 quarters since. The position peaked at $97K in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Smithfield Trust held 239 shares of Charles River Laboratories worth $41K as of Q1 2026.
- Smithfield Trust left its Charles River Laboratories share count unchanged in Q1 2026.
- Charles River Laboratories made up ﹤0.01% of Smithfield Trust's portfolio in Q1 2026, its #623 holding.
- Smithfield Trust first reported a position in Charles River Laboratories in Q4 2017 and has held it in 34 quarters since.
- Smithfield Trust's Charles River Laboratories position peaked at $97K in Q3 2021.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.